Lv11
54 积分 2024-03-04 加入
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
3小时前
已完结
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
11天前
已完结
GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma
26天前
已完结
Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163,641 adults
1个月前
已完结
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
1个月前
已完结
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
2个月前
已完结
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
2个月前
已完结
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
2个月前
已完结
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
2个月前
已完结
Asundexian for Secondary Stroke Prevention
2个月前
已完结
皖公网安备34019202002308
